½ÃÀ庸°í¼­
»óǰÄÚµå
1601120

½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : Åõ¿© °æ·Î, ¸ðµå, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Novel Drug Delivery Systems Market by Route of Administration, Mode, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 191 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2023³â¿¡ 138¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2024³â¿¡´Â 150¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.17%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 255¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

Á¶»ç ¹æ¹ý(NDDS)Àº ÀǾàǰ È­ÇÕ¹°ÀÌ Á¦¾îµÈ ¹æ¹ýÀ¸·Î Àü´ÞÇØ, Ä¡·á ¼º°ú¸¦ Çâ»ó½Ã۱â À§Çؼ­ ¼³°èµÈ ÷´Ü¹æ¹ýÀ» Æ÷ÇÔ ÇÕ´Ï´Ù. NDDS´Â ¾à¹° »ýüÀÌ¿ë·ü, Ç¥Àû ƯÀ̼º, Åõ¿© Ƚ¼ö »è°¨, ºÎÀÛ¿ë ÃÖ¼ÒÈ­¸¦ ³ôÀ̱â À§ÇØ, ÇÊ¿ä ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº Á¾¾çÇÐ, ½Å°æÇÐ, ¸¸¼ºÁúȯ µî, Á¤È®ÇÑ ¾à¹°Àü´ÞÀÌ ÃÖ´ëÁß¿ä·Î ¿©°ÜÁö´Â ºÐ¾ß¿¡¼­ ¸¹ÀÌ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµ ¹üÀ§¿¡´Â ÁÖ·Î º´¿ø, Áø·á¼Ò, ¿¬±¸±â°üÀÌ Æ÷ÇԵǾî Çõ½ÅÀûÀÎ ¾à¹°Àü´Þ ±â¼ú ¿­½ÉÀÎ ¼ÒºñÀÚÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 138¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 150¾ï ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 255¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 9.17%

ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î¼­´Â ¸¸¼ºÁúȯ Áõ°¡, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¼ú Áøº¸, Á¦¾à ±â¾÷¿¡ ÀÇÇÑ ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. °í·ÉÀÚ Àα¸ Áõ°¡¿Í È¿À²ÀûÀÎ Áúº´ °ü¸® Çʿ伺µµ ½ÃÀå ¼ºÀåÀ» ÁöÁöÇÕ´Ï´Ù. ÇöÀç ºñÁî´Ï½º ±âȸ´Â ³ª³ëÅ×Å©³î·¯Áö ÀÀ¿ë, ¸ÂÃãÇü ÀÇ·á, »ýºÐÇØ¼º Àü´Þ ½Ã½ºÅÛ, °æÇÇÆÐÄ¡³ª ÈíÀԱ⠰°Àº ºñħ½ÀÀû Àü´Þ ¹æ¹ý °³¹ß¿¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ(¶§¹®¿¡), ±â¾÷Àº °øµ¿ ¿¬±¸, Àü·«Àû ÆÄÆ®³Ê½Ê, ½º¸¶Æ®¡¤µå·¯±×¡¤µô¸®¹ö¸®¡¤½Ã½ºÅÛÀ» À§ÇÑ AI¿Í IoT ÅëÇÕ¿¡ ÁÖ·Â ÇØ¾ß ÇÕ´Ï´Ù.

±×·¸´Ù°í´Â ÇØµµ, ºñ½Ñ °³¹ßºñ, ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, º¹ÀâÇÑ »ý¹°ÇÐÀû »óÈ£ÀÛ¿ë¿¡ ÀÇÇÑ ÀáÀçÀûÀÎ ¾ÈÀü¼º ¹®Á¦¶ó°í ÇÏ´Â °úÁ¦´Â ¿©ÀüÈ÷ ³²¾Æ ÀÖ¾î ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¦¾àȸ»ç´Â ÀÚÁÖ ÁöÀûÀç»ê±Ç ¹®Á¦¿¡ Á÷¸éÇØ, ±â¼ú Çõ½ÅÀ̳ª ½ÃÀå Âü¿©¸¦ ÀúÇØÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ßºñ¸¦ ÇÕ¸®È­ÇÏ´Â ÇÑÆíÀ¸·Î, ±ÔÁ¦¿¡ ÁذÅÇÑ ¾÷¹«¿¡ ÁÖ·Â ÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ È¯ÀÚ Á᫐ µô¸®¹ö¸®¡¤½Ã½ºÅÛ °³·®, ½ÅÈï ½ÃÀå¿¡ÀÇ ÁøÃâ, ¹ÌÃæÁ· ¿ä±¸ ÀÖ´Â Ä¡·á ¿µ¿ª¿¡ÀÇ ´ëó°¡, Çõ½Å ÃÖ¼± ±æÀÌ µË´Ï´Ù. ½ÃÀå °æÀïÀº °Ý·ÄÇϰí, ´ÙÀ̳ª¹ÍÇϱ⠶§¹®¿¡ Áö¼ÓÀûÇõ½Å°ú Àü·«Àû ¹Îø¼ºÀÌ ¿ä±¸µË´Ï´Ù. °í°´ Á᫐ Çõ½ÅÀ» ¿ì¼±ÇØ, ÃÖ÷´Ü Àç·á °úÇÐÀ» Ȱ¿ëÇÏ´Â °ÍÀ¸·Î, ±â¾÷Àº ÃÖÀûÀÎ ¼ºÀåÀ» ´Þ¼ºÇØ, ½ÃÀå°úÀÇ °ü·Ã¼ºÀ» À¯ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ ÇØ¸í

½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº ¼ö¿ä ¹× °ø±Þ ´ÙÀ̳ª¹ÍÇÑ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ¼­ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐ ÁøÈ­¸¦ ÀÌÇØÇÏ´Â °ÍÀ¸·Î, ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæÀ» ½Ç½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÏ´Â °ÍÀ¸·Î, ±â¾÷Àº Á¤Ä¡Àû, Áö¿ª ¸ñÇ¥, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °Ç³Ê°¡´Â ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖ´Â °Í°ú µ¿½Ã¿¡, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ëÀ̳ª ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼ºÁúȯ À¯Çà°ú ³ëÀÎ Àα¸ ´ëÆøÀûÀÎ Áõ°¡
    • ¾à¹° ¹æÃâ Á¦¾î ±â¼ú Áøº¸
    • ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ °üÇÑ Á¤ºÎ ½ÂÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ °ü·ÃµÈ ±âÁ¸ ÇѰè
  • ½ÃÀå ±âȸ
    • ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ °³¹ßÀ» À§ÇÑ Áö¼ÓÀû Áøº¸
    • ÀÚ°¡ÁÖ»ç µð¹ÙÀ̽º äÅà Áõ°¡
  • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
    • Ä¡·áÁ¦³ª ¾àÁ¦ Àü´Þ¿¡ ÇÊ¿äÇÑ ÇÕº´Áõ°ú Àü¹® Áö½Ä

Porter's Five Forces : ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀ» ¾È³»ÇÏ´Â Àü·« Åø

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå ±¸µµ °æÀï ±¸µµ¸¦ ÀÌÇØÇϱâ À§ÇÑ Áß¿ä ÅøÀÔ´Ï´Ù. Porter's Five Forces¡¤ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ °æÀï·ÂÀ» Æò°¡ÇØ, Àü·«Àû ±âȸ¸¦ ã±â À§ÇÑ ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇØ, ½Å±Ô »ç¾÷ ¼öÀͼºÀ» ÆÇ´ÜÇϴµ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû¿¡ ÀÇÇØ ±â¾÷Àº ÀÚ»ç °­Á¡À» »ì·Á, ¾àÁ¡¿¡ ´ëÃ³ÇØ, ÀáÀçÀûÀÎ °úÁ¦¸¦ ȸÇÇÇÏ´Â °ÍÀ¸·Î, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ¿ÜºÎ·ÎºÎÅÍ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ãȯ°æ ¿äÀÎÀº ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ½ÇÀû ¿ªÇÐÀ» Çü¼ºÇϴµ¥ À־ ¸Å¿ì Áß¿ä ¿ªÇÒÀ» ¿Ï¼öÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» ¾È³»Çϱâ À§Çؼ­ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ´Â °ÍÀ¸·Î, ±â¾÷Àº ÀáÀçÀûÀÎ ¸®½ºÅ©¿Í ±âȸ¸¦ º¸´Ù ÁÁ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®¿¡ ÀÇÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿Çâ º¯È­¸¦ ¿¹ÃøÇØ, ¾ÕÀ» ¿¹ÃøÇÑ Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ½Ç½ÃÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®¿¡ ÀÇÇØ º¥´õ ½ÇÀûÀ» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·üµîÀÇ ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ´Â °ÍÀ¸·Î, °æÀï»ó Æ÷Áö¼Å´×À» ºÐ¸íÈ÷ ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®¿¡ ÀÇÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀÌ ¹àÇôÁ®, º¥´õ´Â °æÀïÀÌ °ÝÈ­ÇÏ´Â °¡¿îµ¥ ÀÚ»ç ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ½Ç½ÃÇϱâ À§Çؼ­ ÇÊ¿äÇÑ Áö°ßÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå º¥´õ ÆÛÆ÷¸Õ½º Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡Çϱâ À§ÇÑ Áß¿ä ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¿¡ ÀÇÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¿¡ ±Ù°ÅÇØ Æò°¡ÇÏ´Â °ÍÀ¸·Î, ¸ñÇ¥¿¡ µû¸¥ ÃæºÐÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÀÇ»ç°áÁ¤À» ½Ç½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù. 4°³ »óÇÑÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇØ, »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥·Î ÃÖÀûÀÎ ÆÄÆ®³Ê³ª ¼Ö·ç¼ÇÀ» ƯÁ¤Çϴµ¥ µµ¿òÀÌ µË´Ï´Ù.

º» º¸°í¼­´Â ÁÖ¿ä ÁÖ¸ñ ºÐ¾ß¸¦ ¸Á¶óÇÑ Á¾ÇÕÀû½ÃÀå ºÐ¼®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù :

1.½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ »ó¼¼ÇÑ ¸®ºä.

2.½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå ¼ºÀå ±âȸ¸¦ ƯÁ¤ÇØ, ±âÁ¸ ºÐ¾ß È®´ë °¡´É¼ºÀ» Æò°¡ÇØ, ÇâÈÄ ¼ºÀåÀ» ÇâÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3.½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° ¹ß¸Å, ¹Ì°³Ã´ Áö¿ª, ¾÷°è ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4.°æÀï Æò°¡¿Í Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÇÏ°Ô ºÐ¼®ÇÏ°í ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦±â°ü ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ ±â¼ú Áøº¸µîÀ» °ËÁõ ÇÕ´Ï´Ù.

5.Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÑ´Ù°í ±â´ëµÇ´Â ÃÖ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, Á¦Ç° Çõ½ÅÀ» ÇÏÀ̶óÀÌÆ® Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾òÀº ´ÙÀ½ ÀÇ»ç°áÁ¤ ÇÒ ¼ö ÀÖµµ·Ï, Áß¿ä Áú¹®¿¡µµ ´äÇϰí ÀÖ½À´Ï´Ù :

1.ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2.ÃÖ°í ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº ¾îµò°¡?

3.½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ ¿µÇâÀ̶õ?

4.ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå Âü¿©¡¤Ã¶Åð Àü·« ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : Åõ¿© °æ·Îº°

  • ÁÖ»ç ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • °æ±¸ ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • Æó ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ

Á¦7Àå ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¸ðµåº°

  • Á¦¾î ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • Á¶Àý ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • Ç¥Àû ¾à¹°Àü´Þ ½Ã½ºÅÛ

Á¦8Àå ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • ¿¬±¸¼¾ÅÍ
  • Àü¹® Ŭ¸®´Ð

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • Novartis AG
  • Societal CDMO
  • Johnson & Johnson Services, Inc.
  • AstraZeneca Plc
  • Abbott Laboratories
  • Sanofi S.A.
  • Terumo Medical Corporation
  • Pfizer Inc.
  • Thermo Fisher Scientific Inc.
  • Enable Injections, Inc.
  • Pacira BioSciences, Inc.
  • Bristol Myers Squibb Company
  • Lonza Group Ltd.
  • Spectrum Pharmaceuticals, Inc.
  • Cospheric LLC
  • Polysciences Inc.
  • Insulet Corporation
  • Bayer AG
  • West Pharmaceutical Services, Inc.
  • Mo-Sci Corporation
  • Merck KGaA
  • Boston Scientific Corporation
  • Merit Medical Systems, Inc.
  • GlaxoSmithKline PLC
  • F. Hoffmann-La Roche Ltd.
LSH 24.12.06

The Novel Drug Delivery Systems Market was valued at USD 13.83 billion in 2023, expected to reach USD 15.00 billion in 2024, and is projected to grow at a CAGR of 9.17%, to USD 25.57 billion by 2030.

The scope of Novel Drug Delivery Systems (NDDS) encompasses advanced methodologies designed to deliver pharmaceutical compounds in a controlled manner to achieve improved therapeutic outcomes. NDDS are essential because they enhance drug bioavailability, target specificity, reduce dosing frequency, and minimize side effects. These systems are highly applicable in areas such as oncology, neurology, and chronic conditions where precise drug delivery is paramount. The end-use scope primarily includes hospitals, clinics, and research institutes, which are avid consumers of innovative drug delivery technologies.

KEY MARKET STATISTICS
Base Year [2023] USD 13.83 billion
Estimated Year [2024] USD 15.00 billion
Forecast Year [2030] USD 25.57 billion
CAGR (%) 9.17%

Key market drivers include the rising prevalence of chronic diseases, technological advancements in biotechnology, and increased R&D investments by pharmaceutical companies. The growing geriatric population and the need for efficient disease management also bolster market growth. Current opportunities lie in nanotechnology applications, personalized medicine, biodegradable delivery systems, and the development of non-invasive delivery methods like transdermal patches and inhalers. To capitalize on these opportunities, businesses should focus on collaborative research, strategic partnerships, and the integration of AI and IoT for smart drug delivery systems.

Nevertheless, challenges such as high development costs, stringent regulatory frameworks, and potential safety issues due to complex biological interactions persist, potentially impeding market growth. Moreover, pharmaceutical companies often face intellectual property rights issues, which can stall innovation and market entry. Rationalizing R&D expenditure while focusing on regulatory-compliant practices is crucial. Additionally, refining patient-centric delivery systems, expanding to emerging markets, and addressing therapeutic areas with unmet needs represent the best innovation avenues. The market's nature is highly competitive and dynamic, requiring continuous innovation and strategic agility. By prioritizing customer-centric innovation and leveraging cutting-edge materials science, companies can achieve optimal growth and maintain market relevance.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Novel Drug Delivery Systems Market

The Novel Drug Delivery Systems Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of Chronic Diseases and Significant Rise in Geriatric Population
    • Advancements in Controlled Drug Release Technologies
    • Government Approvals for Novel Drug Delivery Systems
  • Market Restraints
    • Existing Limitations Associated with Novel Drug Delivery System
  • Market Opportunities
    • Ongoing Advancements for Development of Novel Drug Delivery Systems
    • Rising Adoption of Self-Injectable Devices
  • Market Challenges
    • Complications and Expertise Required in Delivering Therapeutics and Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Novel Drug Delivery Systems Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Novel Drug Delivery Systems Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Novel Drug Delivery Systems Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Novel Drug Delivery Systems Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Novel Drug Delivery Systems Market

A detailed market share analysis in the Novel Drug Delivery Systems Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Novel Drug Delivery Systems Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Novel Drug Delivery Systems Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Novel Drug Delivery Systems Market, highlighting leading vendors and their innovative profiles. These include Novartis AG, Societal CDMO, Johnson & Johnson Services, Inc., AstraZeneca Plc, Abbott Laboratories, Sanofi S.A., Terumo Medical Corporation, Pfizer Inc., Thermo Fisher Scientific Inc., Enable Injections, Inc., Pacira BioSciences, Inc., Bristol Myers Squibb Company, Lonza Group Ltd., Spectrum Pharmaceuticals, Inc., Cospheric LLC, Polysciences Inc., Insulet Corporation, Bayer AG, West Pharmaceutical Services, Inc., Mo-Sci Corporation, Merck KGaA, Boston Scientific Corporation, Merit Medical Systems, Inc., GlaxoSmithKline PLC, and F. Hoffmann-La Roche Ltd..

Market Segmentation & Coverage

This research report categorizes the Novel Drug Delivery Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Injectable Drug Delivery Systems, Oral Drug Delivery Systems, Pulmonary Drug Delivery Systems, and Transdermal Drug Delivery Systems.
  • Based on Mode, market is studied across Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Targeted Drug Delivery Systems.
  • Based on End-User, market is studied across Hospital, Research Centers, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Chronic Diseases and Significant Rise in Geriatric Population
      • 5.1.1.2. Advancements in Controlled Drug Release Technologies
      • 5.1.1.3. Government Approvals for Novel Drug Delivery Systems
    • 5.1.2. Restraints
      • 5.1.2.1. Existing Limitations Associated with Novel Drug Delivery System
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Advancements for Development of Novel Drug Delivery Systems
      • 5.1.3.2. Rising Adoption of Self-Injectable Devices
    • 5.1.4. Challenges
      • 5.1.4.1. Complications and Expertise Required in Delivering Therapeutics and Drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Route of Administration: Rising adoption of injectable drug delivery systems for chronic disease management
    • 5.2.2. End-User: Increasing use of novel drug delivery systems in the hospital due to budget constraints and the necessity to cater to a larger patient base
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Novel Drug Delivery Systems Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Injectable Drug Delivery Systems
  • 6.3. Oral Drug Delivery Systems
  • 6.4. Pulmonary Drug Delivery Systems
  • 6.5. Transdermal Drug Delivery Systems

7. Novel Drug Delivery Systems Market, by Mode

  • 7.1. Introduction
  • 7.2. Controlled Drug Delivery Systems
  • 7.3. Modulated Drug Delivery Systems
  • 7.4. Targeted Drug Delivery Systems

8. Novel Drug Delivery Systems Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Research Centers
  • 8.4. Specialty Clinics

9. Americas Novel Drug Delivery Systems Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Novel Drug Delivery Systems Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Novel Drug Delivery Systems Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Novel drug delivery one-stop shop
    • 12.3.2. Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
    • 12.3.3. Kindeva Drug Delivery acquires Summit Biosciences

Companies Mentioned

  • 1. Novartis AG
  • 2. Societal CDMO
  • 3. Johnson & Johnson Services, Inc.
  • 4. AstraZeneca Plc
  • 5. Abbott Laboratories
  • 6. Sanofi S.A.
  • 7. Terumo Medical Corporation
  • 8. Pfizer Inc.
  • 9. Thermo Fisher Scientific Inc.
  • 10. Enable Injections, Inc.
  • 11. Pacira BioSciences, Inc.
  • 12. Bristol Myers Squibb Company
  • 13. Lonza Group Ltd.
  • 14. Spectrum Pharmaceuticals, Inc.
  • 15. Cospheric LLC
  • 16. Polysciences Inc.
  • 17. Insulet Corporation
  • 18. Bayer AG
  • 19. West Pharmaceutical Services, Inc.
  • 20. Mo-Sci Corporation
  • 21. Merck KGaA
  • 22. Boston Scientific Corporation
  • 23. Merit Medical Systems, Inc.
  • 24. GlaxoSmithKline PLC
  • 25. F. Hoffmann-La Roche Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦